Company: SCLXW
Filing Date: 2025-07-23
Form Type: 424B3
Source: 0001193125-25-163077
Chunk: 237

Company: Scilex Holding Co
Filing Date: 2025-07-23
Form: 424B3
Chunk 237
---
arrants).

(e) Purchaser agrees to file with the Securities and Exchange Commission a Current Report on Form 8-K describing the terms of this Agreement as soon as practicable following the date hereof and in any event within one (1) Business Day following the date hereof.

(f) From the date hereof through the earlier of (i) the Trigger Date and (ii) the termination of this Agreement
pursuant to , Purchaser shall not, directly or indirectly, offer, issue, sell or grant, or enter into any agreement or contractual obligation (including in connection with any financing transaction) to offer,
issue, sell or grant any Capital Stock or Equity Rights (disregarding the words “then-outstanding” in the definition thereof) to any Person in, or with respect to, Purchaser (any such transaction, an “”), at
a per share purchase price of lower than $6.00 in each case, without the prior written consent of Oramed.

(g)
Notwithstanding anything herein to the contrary (including , if at any time Purchaser undertakes any Equity Issuance (whether or not at a per share price that is lower than $6.00), seventy percent (70%) of the
cash proceeds (net of underwriting discounts, accounting, investment banking or broker fees and sales commissions and other reasonable and documented out-of-pocket costs
and expenses of the Company associated therewith, in each case, paid to non-Affiliates) of such Equity Issuance as are available after the making of any required payments under the terms of the Tranche A Note
and the Tranche B Note (such amount with respect to any Equity Issuance, the applicable “”) shall be paid to Oramed in the following order of priority: (i) to satisfy any portion of the Option Fee which
was not paid on the applicable Option Closing Payment Date (together with any interest accrued

9

thereon) pursuant to until such portion of the Option Fee (together with any accrued interest) is fully-paid, (ii) as a prepayment on any portion of
the Option Fee not yet due and payable pursuant to until such portion of the Option Fee is fully paid, and (iii), subject to Oramed’s prior written consent and approval, as a partial exercise of the Option
in respect of a number of Warrant Shares equal to the applicable Equity Financing Amount divided by Per Share Price until the Purchase Price is fully paid (and Purchaser shall issue to